You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

A Novel Grading System for Clear Cell Renal Cell Carcinoma Incorporating Tumor Necrosis

Delahunt, Brett MD, FRCPA, FRCPath*; McKenney, Jesse K. MD; Lohse, Christine M. MS; Leibovich, Bradley C. MD§; Thompson, Robert Houston MD§; Boorjian, Stephen A. MD§; Cheville, John C. MD

American Journal of Surgical Pathology:
doi: 10.1097/PAS.0b013e318270f71c
Original Articles
Abstract

Grading of renal cell carcinoma (RCC) has prognostic significance, and there is recent consensus by the International Society of Urological Pathology (ISUP) that for clear cell and papillary RCC, grading should primarily be based on nucleolar prominence. Microscopic tumor necrosis also predicts outcome independent of tumor grading. This study was undertaken to assess whether the incorporation of microscopic tumor necrosis into the ISUP grading system provides survival information superior to ISUP grading alone. Data on 3017 patients treated surgically for clear cell RCC, 556 for papillary RCC, and 180 for chromophobe RCC were retrieved from the Mayo Clinic Registry. Median follow-up periods were 8.9, 9.7, and 8.5 years, respectively. Four proposed grades were defined: grade 1: ISUP grade 1+ISUP grade 2 without necrosis; grade 2: ISUP grade 2 with necrosis+ISUP grade 3 without necrosis; grade 3: ISUP grade 3 with necrosis+ISUP grade 4 without necrosis; grade 4: ISUP grade 4 with necrosis or sarcomatoid/rhabdoid tumors. There was a significant difference in survival between each of the grades for clear cell RCC, and the concordance index was superior to that of ISUP grading. The proposed grading system also outperformed the ISUP grading system when cases were stratified according to the TNM stage. Similar results were not obtained for papillary RCC or chromophobe RCC. We conclude that grading for clear cell RCC should be based on nucleolar prominence and necrosis, that ISUP grading should be used for papillary RCC, and that chromophobe RCC should not be graded.

Author Information

*Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand

Division of Pathology, The Cleveland Clinic Foundation, Cleveland, OH

Departments of Health Sciences Research

§Urology

Pathology, Mayo Clinic, Rochester, MN

Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Correspondence: Brett Delahunt, MD, FRCPA, FRCPath, Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, 23A Mein Street, Wellington, New Zealand 6021 (e-mail: bd@wnmeds.ac.nz).

© 2013 Lippincott Williams & Wilkins, Inc.